EP1348343B1 - Dietary supplement composition - Google Patents
Dietary supplement composition Download PDFInfo
- Publication number
- EP1348343B1 EP1348343B1 EP03002929A EP03002929A EP1348343B1 EP 1348343 B1 EP1348343 B1 EP 1348343B1 EP 03002929 A EP03002929 A EP 03002929A EP 03002929 A EP03002929 A EP 03002929A EP 1348343 B1 EP1348343 B1 EP 1348343B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- preparation according
- preparation
- present
- maricha
- ayurvedic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 14
- 239000006041 probiotic Substances 0.000 claims abstract description 16
- 230000000529 probiotic effect Effects 0.000 claims abstract description 16
- 235000018291 probiotics Nutrition 0.000 claims abstract description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 241000894006 Bacteria Species 0.000 claims abstract description 7
- 229930013930 alkaloid Natural products 0.000 claims abstract description 4
- 150000003797 alkaloid derivatives Chemical class 0.000 claims abstract description 4
- 239000004310 lactic acid Substances 0.000 claims abstract description 4
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 4
- 239000011669 selenium Substances 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- 235000011649 selenium Nutrition 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 229920001202 Inulin Polymers 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 102000038379 digestive enzymes Human genes 0.000 claims description 3
- 108091007734 digestive enzymes Proteins 0.000 claims description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 3
- 229940029339 inulin Drugs 0.000 claims description 3
- 235000013406 prebiotics Nutrition 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 229940093797 bioflavonoids Drugs 0.000 claims description 2
- 239000006096 absorbing agent Substances 0.000 claims 3
- 239000012676 herbal extract Substances 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000011573 trace mineral Substances 0.000 claims 1
- 235000013619 trace mineral Nutrition 0.000 claims 1
- 235000013311 vegetables Nutrition 0.000 claims 1
- 235000013599 spices Nutrition 0.000 abstract description 12
- 244000052616 bacterial pathogen Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
Definitions
- the invention relates to a dietary supplement preparation containing probiotic cultures with a predetermined proportion of living probiotic lactic acid bacteria and a spice extract according to the Ayurvedic principle - Maricha as alkaloid.
- a dietary supplement preparation containing probiotic cultures with a predetermined proportion of living probiotic lactic acid bacteria and a spice extract according to the Ayurvedic principle - Maricha as alkaloid.
- Such a preparation is already known in the form of a medicine from US Pat. No. 6,080,401.
- Spice extract according to the ayurvedic principle - Maricha seems to act as a kind of catalyst to better penetrate the biological barriers, especially intestinal mucosa and cell walls.
- the object of the present invention over the prior art mentioned above is to provide a dietary supplement preparation which enhances this beneficial effect of spice extract according to the Ayurvedic principle - Maricha.
- a dietary supplement preparation containing in addition to a spice extract according to the Ayurvedic principle - Maricha as alkaloid, probiotic cultures with a predetermined proportion of living probiotic lactic acid bacteria, prebiotic fructooligosaccharides and / or inulin to promote the probiotic cultures and a plurality of different plant digestive enzymes.
- the dietary supplement preparation further contains at least one substance acting as radical scavenger.
- the radical scavenger is purposefully transported to the intended sites of action.
- the at least one substance acting as radical scavenger may comprise bioflavonoids.
- the at least one radical scavenging substance may comprise one or more antioxidants.
- the absorption of selenium is known to be enhanced by spice extract according to the Ayurvedic principle - Maricha.
- the dietary supplement preparation is also mixed with selenium, wherein the absorption achieved by the synergetic mode of action of proprobiotic Cultures on the one hand and spice extract according to the Ayurvedic principle - on the other hand, Maricha is even more enhanced.
- the spice extract according to the Ayurvedic principle - Maricha contained in a concentration corresponding to a daily dose of 1 to 10 mg, preferably 3 to 7 mg, more preferably about 5 mg per day.
- probiotic cultures with a germ amount of 10 7 to 10 11 germs, preferably 10 8 to 10 10 germs, in particular of about 10 9 germs contained.
- the amounts of germs given here are based on the number of live or viable germs at the time of incorporation into the preparation.
- Various measures, also specified in the present application, can ensure that the highest possible proportion of these germs also reaches the active site in the intestinal area alive.
- Supplements such as carriers or flavorings may continue to be included in the dietary supplement preparation.
- the proportion by weight of the additives in the preparation is in a range between 20 and 95% by weight, preferably in the range between 60 and 95% by weight.
- the preparation may be in liquid form, in the form of an emulsion or in any other desired form.
- the preparation is provided in powdered form for the preparation of an aqueous solution.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Die Erfindung betrifft ein Nahrungsergänzungsmittelpräparat enthaltend probiotische Kulturen mit einem vorbestimmten Anteil an lebenden probiotischen Milchsäurebakterien sowie einen Gewürzextrakt nach dem ayurvedischen Prinzip - Maricha als Alkaloid. Ein derartiges Präparat ist in Form einer Arznei bereits aus der US 6 080 401 bekannt.The invention relates to a dietary supplement preparation containing probiotic cultures with a predetermined proportion of living probiotic lactic acid bacteria and a spice extract according to the Ayurvedic principle - Maricha as alkaloid. Such a preparation is already known in the form of a medicine from US Pat. No. 6,080,401.
Es ist bereits bei einer Vielzahl von Nahrungsergänzungsmittelpräparaten, beispielsweise bei der Verabreichung von Beta-Karotin, Selen, Vitamin B6, Vitamin C, Vitamin A, Vitamin A + D festgestellt worden, dass die Beimengung eines Gewürzextraktes nach dem ayurvedischen Prinzip - Maricha eine resorptionsverstärkende Wirkung auslöst. Gewürzextrakt nach dem ayurvedischen Prinzip - Maricha scheint hier als eine Art Katalysator zu wirken, um die biologischen Barrieren, insbesondere Darmschleimhaut und Zellwände, besser zu durchdringen.It has already been found in a variety of dietary supplements, for example in the administration of beta-carotene, selenium, vitamin B6, vitamin C, vitamin A, vitamin A + D that the addition of a spice extract according to the Ayurvedic principle - Maricha an absorption-enhancing effect triggers. Spice extract according to the ayurvedic principle - Maricha seems to act as a kind of catalyst to better penetrate the biological barriers, especially intestinal mucosa and cell walls.
Die Aufgabe der vorliegenden Erfindung besteht gegenüber dem eingangs genannten Stand der Technik darin, ein Nahrungsergänzungsmittelpräparat bereitzustellen, welches diese vorteilhafte Wirkung von Gewürzextrakt nach dem ayurvedischen Prinzip - Maricha noch verstärkt.The object of the present invention over the prior art mentioned above is to provide a dietary supplement preparation which enhances this beneficial effect of spice extract according to the Ayurvedic principle - Maricha.
Diese Aufgabe wird gelöst durch ein Nahrungsergänzungsmittelpräparat enthaltend neben einem Gewürzextrakt nach dem ayurvedischen Prinzip - Maricha als Alkaloid, probiotische Kulturen mit einem vorbestimmten Anteil an lebenden probiotischen Milchsäurebakterien, präbiotische Fruktooligosaccharide und/oder Inulin zur Förderung der probiotischen Kulturen sowie eine Mehrzahl verschiedener pflanzlicher Verdauungsenzyme.This object is achieved by a dietary supplement preparation containing in addition to a spice extract according to the Ayurvedic principle - Maricha as alkaloid, probiotic cultures with a predetermined proportion of living probiotic lactic acid bacteria, prebiotic fructooligosaccharides and / or inulin to promote the probiotic cultures and a plurality of different plant digestive enzymes.
Es hat sich gezeigt, dass die Wirkungsweise von Gewürzextrakt nach dem ayurvedischen Prinzip - Maricha noch unterstützt werden kann, wenn durch den Einsatz von probiotischen Kulturen eine insgesamt positive Darmflora und damit eine günstige Situation im Darmtrakt insbesondere an der Darmschleimhaut geschaffen werden kann. Die Darmschleimhaut wird durch die probiotischen Kulturen für besondere Wirkung des Gewürzextrakts nach dem ayurvedischen Prinzip - Maricha zweckmäßig vorbereitet. Um die probiotischen Kulturen in möglichst hoher Keimzahl an der Wirkungsstätte, d. h. im Darm, zu erhalten, sind dabei auch präbiotische Fruktooligosaccharide und/oder Inulin enthalten. Weiterhin ist eine Mehrzahl verschiedener pflanzlicher Verdauungsenzyme im erfindungsgemäßen Nahrungsergänzungsmittelpräparat enthalten.It has been shown that the effect of spice extract according to the Ayurvedic principle - Maricha can still be supported if the use of probiotic cultures an overall positive intestinal flora and thus a favorable situation in the intestinal tract, especially on the intestinal mucosa can be created. The intestinal mucosa is prepared by the probiotic cultures for special effect of the spice extract according to the Ayurvedic principle - Maricha appropriate. To the probiotic cultures in the highest possible number of germs at the site, d. H. in the intestine, prebiotic fructooligosaccharides and / or inulin are included. Furthermore, a plurality of different plant digestive enzymes are contained in the dietary supplement preparation according to the invention.
In einer vorteilhaften Ausgestaltung enthält das Nahrungsergänzungsmittelpräparat weiterhin mindestens eine als Radikalfänger wirkende Substanz. Durch die in synergetischer Weise wirkenden probiotischen Kulturen einerseits und den Gewürzextrakt nach dem ayurvedischen Prinzip - Maricha andererseits wird der Radikalfänger zielgerichtet an die vorgesehenen Wirkungsorte transportiert.In an advantageous embodiment, the dietary supplement preparation further contains at least one substance acting as radical scavenger. On the one hand the synergistic probiotic cultures on the one hand and the spice extract on the ayurvedic principle - Maricha on the other hand, the radical scavenger is purposefully transported to the intended sites of action.
In einer konkreten Ausgestaltung kann die mindestens eine als Radikalfänger wirkende Substanz Bioflavonoide umfassen.In a specific embodiment, the at least one substance acting as radical scavenger may comprise bioflavonoids.
Alternativ oder ergänzend kann die mindestens eine als Radikalfänger wirkende Substanz ein oder mehrere Antioxidantien umfassen.Alternatively or additionally, the at least one radical scavenging substance may comprise one or more antioxidants.
Weiterhin ist es in zweckmäßiger Weise vorgesehen, dem Nahrungsergänzungsmittelpräparat eine Mehrzahl verschiedener löslicher und/oder unlöslicher Ballaststoffe beizumischen.Furthermore, it is expedient to add to the dietary supplement preparation a plurality of different soluble and / or insoluble fiber.
Die Resorption von Selen wird bekanntermaßen durch Gewürzextrakt nach dem ayurvedischen Prinzip - Maricha gesteigert. In einer vorteilhaften Ausgestaltung wird dem Nahrungsergänzungsmittelpräparat auch Selen beigemischt, wobei die erreichte Resorption durch die synergetische Wirkungsweise von proprobiotischen Kulturen einerseits und Gewürzextrakt nach dem ayurvedischen Prinzip - Maricha andererseits nochmals gesteigert ist.The absorption of selenium is known to be enhanced by spice extract according to the Ayurvedic principle - Maricha. In an advantageous embodiment, the dietary supplement preparation is also mixed with selenium, wherein the absorption achieved by the synergetic mode of action of proprobiotic Cultures on the one hand and spice extract according to the Ayurvedic principle - on the other hand, Maricha is even more enhanced.
In einer konkreten Ausgestaltung ist das Gewürzextrakt nach dem ayurvedischen Prinzip - Maricha in einer Konzentration enthalten, die einer Tagesdosis von 1 bis 10 mg, vorzugsweise 3 bis 7 mg, besonders bevorzugt etwa 5 mg pro Tag, entspricht.In a specific embodiment, the spice extract according to the Ayurvedic principle - Maricha contained in a concentration corresponding to a daily dose of 1 to 10 mg, preferably 3 to 7 mg, more preferably about 5 mg per day.
Bevorzugtermaßen sind bezogen auf eine Tagesdosis von 5 mg in dem erfindungsgemäßen Präparat probiotische Kulturen mit einer Keimmenge von 107 bis 1011 Keimen, vorzugsweise 108 bis 1010 Keimen, insbesondere von etwa 109 Keimen enthalten. Die hier angegebenen Keimmengen beziehen sich auf die Anzahl lebender bzw. lebensfähiger Keime zum Zeitpunkt der Beimischung in das Präparat. Durch verschiedene, auch in der vorliegenden Anmeldung angegebene Maßnahmen lässt sich gewährleisten, dass ein möglichst hoher Anteil dieser Keime auch lebend an die Wirkstelle im Darmbereich gelangt.Preferably, based on a daily dose of 5 mg in the preparation according to the invention probiotic cultures with a germ amount of 10 7 to 10 11 germs, preferably 10 8 to 10 10 germs, in particular of about 10 9 germs contained. The amounts of germs given here are based on the number of live or viable germs at the time of incorporation into the preparation. Various measures, also specified in the present application, can ensure that the highest possible proportion of these germs also reaches the active site in the intestinal area alive.
In dem Nahrungsergänzungsmittelpräparat können weiterhin Zuschläge wie Träger- oder Geschmacksstoffe enthalten sein. In einer konkreten Ausgestaltung beläuft sich der Gewichtsanteil der Zuschläge am Präparat in einem Bereich zwischen 20 und 95 Gew.%, vorzugsweise im Bereich zwischen 60 und 95 Gew.%.Supplements such as carriers or flavorings may continue to be included in the dietary supplement preparation. In a specific embodiment, the proportion by weight of the additives in the preparation is in a range between 20 and 95% by weight, preferably in the range between 60 and 95% by weight.
Das Präparat kann in flüssiger Form, in Form einer Emulsion oder in einer anderen beliebigen Form vorliegen. Bevorzugtermaßen ist das Präparat in pulvriger Form zur Herstellung einer wässrigen Lösung bereitgestellt.The preparation may be in liquid form, in the form of an emulsion or in any other desired form. Preferably, the preparation is provided in powdered form for the preparation of an aqueous solution.
Claims (11)
- Nutritional supplement preparation containing:- probiotic cultures having a predetermined proportion of living probiotic lactic acid bacteria,- a herbal extract according to the ayurvedic principle - maricha as alkaloid,- prebiotic fructooligosaccharides and/or inulin for the promotion of the probiotic cultures and- a plurality of different vegetable digestive enzymes.
- Nutritional supplement preparation according to claim 1, characterised in that at least one substance acting as a free-radial absorber is also present.
- Preparation according to claim 2, characterised in that the at least one substance acting as a free-radial absorber comprises bioflavonoids.
- Preparation according to claim 2 or 3, characterised in that the at least one substance acting as a free-radial absorber comprises one or more anti-oxidants.
- Preparation according to one of claims 1 to 4, characterised in that a plurality of different soluble and/or insoluble bulk materials are also present.
- Nutritional supplement preparation according to one of claims 1 to 5, characterised in that the trace element selenium is present.
- Preparation according to one of claims 1 to 6, characterised in that the herbal extract according to the ayurvedic principle - maricha is present in a concentration which corresponds to a daily dose of 1 to 10 mg, preferably 3 to 7 mg, particularly preferably about 5 mg per day.
- Preparation according to one of claims 1 to 7, characterised in that probiotic cultures having a bacterial quantity of 107 to 1011 bacteria, preferably 108 to 1010 bacteria, in particular of about 109 bacteria, are present, based on a daily dose of 5 mg.
- Preparation according to one of claims 1 to 8, characterised in that the preparation also contains additives, such as excipients or flavourings.
- Preparation according to claim 9, characterised in that the weight proportion of the additives in the preparation lies in the range between 20 and 95 weight per cent, preferably in the range between 60 and 95 weight per cent.
- Preparation according to one of claims 1 to 10, characterised in that the preparation exists in pulverulent form for the production of an aqueous solution.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10214297A DE10214297A1 (en) | 2002-03-28 | 2002-03-28 | Food supplement preparation |
| DE10214297 | 2002-03-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1348343A1 EP1348343A1 (en) | 2003-10-01 |
| EP1348343B1 true EP1348343B1 (en) | 2006-05-17 |
Family
ID=27798257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP03002929A Expired - Lifetime EP1348343B1 (en) | 2002-03-28 | 2003-02-10 | Dietary supplement composition |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1348343B1 (en) |
| AT (1) | ATE326148T1 (en) |
| DE (2) | DE10214297A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106666738A (en) * | 2016-12-13 | 2017-05-17 | 合肥赛为智慧医疗有限公司 | Composition used for improving metabolic disorder status of human body and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080401A (en) * | 1998-11-19 | 2000-06-27 | Reddy; Malireddy S. | Herbal and pharmaceutical drugs enhanced with probiotics |
| AU2001276537A1 (en) * | 2000-08-08 | 2002-02-18 | Paula Frances Buchanan-Baillie-Hamilton | Slimming system |
-
2002
- 2002-03-28 DE DE10214297A patent/DE10214297A1/en not_active Withdrawn
-
2003
- 2003-02-10 AT AT03002929T patent/ATE326148T1/en not_active IP Right Cessation
- 2003-02-10 DE DE50303331T patent/DE50303331D1/en not_active Expired - Lifetime
- 2003-02-10 EP EP03002929A patent/EP1348343B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1348343A1 (en) | 2003-10-01 |
| DE10214297A1 (en) | 2003-10-23 |
| ATE326148T1 (en) | 2006-06-15 |
| DE50303331D1 (en) | 2006-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60207877T2 (en) | Composition containing procyanidins for reducing appetite in mammals | |
| DE3151245C2 (en) | ||
| DE69917784T2 (en) | LIQUID CHITOSAN-CONTAINING COMPOSITIONS AND METHODS OF PRODUCTION AND USE | |
| DE69907606T2 (en) | Composition containing Panax pseudo ginseng and Eucommiae ulmoides | |
| DE69823661T2 (en) | FUNCTIONAL FOOD PREPARATION | |
| DE102006056454A1 (en) | Taste-free, granular nutritional supplement, useful e.g. for preventing osteoporosis and psoriasis, contains synergistic combination of Spirulina, Chlorella and Lithothamnium algae | |
| DE60030845T2 (en) | MEDICINES, FOOD AND ORAL COMPOSITIONS CONTAINING STYLING-ARTIFICIAL CONNECTIONS | |
| EP1348343B1 (en) | Dietary supplement composition | |
| WO2002100188A1 (en) | Animal feed additive for intestinal stabilization and for promoting digestion in domestic animals | |
| DE69918152T2 (en) | TREATMENT OF DIGESTIVE DISORDER | |
| DE20221170U1 (en) | Nutritional supplement preparation, useful for improving condition of the intestinal tract, comprising probiotic culture containing living lactic acid bacteria and spice extract obtained by the ayurvedic principle containing maricha | |
| EP1530479A2 (en) | Medicament, food supplement, and fodder additive | |
| EP0717632B1 (en) | A food additive for improving immunity | |
| DE10143146B4 (en) | Anti-arthritic preparation and its use | |
| EP0256353A2 (en) | Pharmaceutical therapy against the bad absorption of food or oral drugs | |
| DE102008006363A1 (en) | Horse food for the production of a healthy intestinal flora of horse, comprises a first feedstuff component and a second feedstuff component, which has a prebiotic effective substance and is provided as a concentrate of topinambur | |
| DE102006031441B4 (en) | Oral creatine supplement, and method of making the same | |
| DE2845570A1 (en) | COMPOSITION CONTAINING HONEY | |
| DE202010001716U1 (en) | Melissa, magnesium, basic salts and B vitamins containing composition | |
| DE19606024C2 (en) | Mineral feed for farm animals and process for their production | |
| EP4248956A2 (en) | Pharmaceutical composition comprising cannabidiol | |
| DE60216258T2 (en) | PLANT SEA OIL-CONTAINING COMPOSITION | |
| DE1904562A1 (en) | Medicinal products containing 5ss-glycocholanic acid or 5ss-taurocholanic acid | |
| DE2618269A1 (en) | AGENT FOR ORAL ADMINISTRATION TO PETS WITHOUT CELLULOSE DIGESTION IN THE RUMEN | |
| EP0125322B1 (en) | Process for the use of ergotropic agent combinations in the breeding and the fattening of useful animals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO |
|
| 17P | Request for examination filed |
Effective date: 20031110 |
|
| 17Q | First examination report despatched |
Effective date: 20040312 |
|
| AKX | Designation fees paid |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060517 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20060517 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060517 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060517 Ref country code: IE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060517 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060517 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060517 |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 36/00 20060101ALI20060328BHEP Ipc: A23L 1/30 20060101AFI20060328BHEP |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20060517 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN |
|
| REF | Corresponds to: |
Ref document number: 50303331 Country of ref document: DE Date of ref document: 20060622 Kind code of ref document: P |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060817 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060817 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060828 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061017 |
|
| NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
| ET | Fr: translation filed | ||
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FD4D |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070228 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070228 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070228 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20070220 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| BERE | Be: lapsed |
Owner name: PM-INTERNATIONAL AG Effective date: 20070228 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070228 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060818 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060817 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070210 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060517 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060517 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061118 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060517 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20220222 Year of fee payment: 20 Ref country code: DE Payment date: 20220225 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20220224 Year of fee payment: 20 Ref country code: FR Payment date: 20220224 Year of fee payment: 20 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 50303331 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20230209 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20230209 |